Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 1
1941 1
1961 1
1963 1
1966 1
1969 1
1970 2
1971 2
1972 2
1974 1
1979 1
1981 2
1982 2
1983 5
1984 4
1985 2
1987 1
1988 1
1989 1
1990 3
1991 3
1992 1
1993 3
1994 4
1995 4
1996 3
1997 7
1998 10
1999 5
2000 3
2001 2
2002 4
2003 5
2004 2
2005 2
2006 2
2007 1
2008 4
2009 1
2010 2
2011 7
2012 4
2013 4
2014 5
2015 1
2016 6
2017 4
2018 4
2020 4
2021 6
2022 3
2023 5
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Lebwohl MG, et al. Among authors: burnett p. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. JAMA. 2022. PMID: 36125472 Free PMC article.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Zirwas MJ, Draelos ZD, DuBois J, Kircik LH, Moore AY, Stein Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green LJ, Guenthner ST, Ferris LK, Forman SB, Kempers SE, Lain E, Lynde CW, Pariser DM, Toth DP, Yamauchi PS, Higham RC, Krupa D, Burnett P, Berk DR. Zirwas MJ, et al. Among authors: burnett p. JAMA Dermatol. 2023 Jun 1;159(6):613-620. doi: 10.1001/jamadermatol.2023.0846. JAMA Dermatol. 2023. PMID: 37133856 Free PMC article. Clinical Trial.
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Blauvelt A, Draelos ZD, Stein Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, Forman SB, Gooderham M, Green L, Guenthner ST, Hebert AA, Lain E, Moore AY, Papp KA, Zirwas M, Kato S, Snyder S, Krupa D, Burnett P, Berk DR, Chu DH. Blauvelt A, et al. Among authors: burnett p. J Am Acad Dermatol. 2024 May;90(5):986-993. doi: 10.1016/j.jaad.2023.12.065. Epub 2024 Jan 20. J Am Acad Dermatol. 2024. PMID: 38253129 Free article. Clinical Trial.
Methionine epimerization in cyclic peptides.
Jadhav PD, Shen J, Burnett PG, Yang J, Sammynaiken R, Reaney MJT. Jadhav PD, et al. Among authors: burnett pg. RSC Adv. 2021 Jun 11;11(34):20859-20864. doi: 10.1039/d1ra04260b. eCollection 2021 Jun 9. RSC Adv. 2021. PMID: 35479339 Free PMC article.
Biological challenges of BRAF inhibitor therapy.
Puzanov I, Burnett P, Flaherty KT. Puzanov I, et al. Among authors: burnett p. Mol Oncol. 2011 Apr;5(2):116-23. doi: 10.1016/j.molonc.2011.01.005. Epub 2011 Feb 16. Mol Oncol. 2011. PMID: 21393075 Free PMC article. Review.
Erythema elevatum diutinum.
Burnett PE, Burgin S. Burnett PE, et al. Dermatol Online J. 2003 Oct;9(4):37. Dermatol Online J. 2003. PMID: 14594610 Free article.
Glycine-containing flaxseed orbitides.
Burnett PG, Jadhav PD, Okinyo-Owiti DP, Poth AG, Reaney MJ. Burnett PG, et al. J Nat Prod. 2015 Apr 24;78(4):681-8. doi: 10.1021/np5008558. Epub 2015 Mar 17. J Nat Prod. 2015. PMID: 25781981
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Stein Gold L, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ, Hong HC, Kempers SE, Kircik LH, Lebwohl M, Loo WJ, Nahm WK, Papp KA, Stewart D, Toth DP, Zirwas M, Krupa D, Snyder S, Burnett P, Higham R, Berk DR. Stein Gold L, et al. Among authors: burnett p. J Am Acad Dermatol. 2024 Aug;91(2):273-280. doi: 10.1016/j.jaad.2024.03.030. Epub 2024 Mar 29. J Am Acad Dermatol. 2024. PMID: 38556093 Free article. Clinical Trial.
154 results